Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (CELZ)
Overview
Creative Medical Technology Holdings, Inc. is a Phoenix, Arizona-based, commercial-stage biotechnology company, founded in 1998, developing biological therapeutics across immunotherapy, endocrinology, urology, neurology, and orthopedics using perinatal tissue-derived cells. The company is extremely small in scale, with only about 4 employees and fiscal 2025 revenue of just $6,000, down 45% year over year, against a net loss of $6.04 million. Its market capitalization is about $7.3 million, with the stock trading around $1.11 as of early September 2026. This is a pre-commercial, research-and-development-stage company whose value depends almost entirely on the future success of its pipeline of experimental regenerative therapies rather than any current product revenue.
What They Do & How They Make Money
Creative Medical Technology's business model centers on developing and eventually commercializing cell-based regenerative therapies derived from perinatal (placental/umbilical) tissue. Its pipeline includes CaverStem, an outpatient stem cell procedure for erectile dysfunction; FemCelz, targeting genital sensitivity loss and vaginal dryness; CELZ-201 (Olastrocel), a perinatal-derived cell therapy currently in the ADAPT clinical trial for chronic lower back pain; Ultrasome, a cell-free regenerative therapy for knee osteoarthritis that reported a 93% response rate in an early pilot study; ImmCelz (CELZ-100), a personalized immune-therapy platform; and MyeloCelz, an exosome-based immunotherapy candidate for Type 1 diabetes. The company also runs Project PHOENIX, a veteran support registry and biodefense initiative. Today's minimal revenue reflects limited procedure volume from its most commercially advanced offerings (like CaverStem, delivered through physician clinics), while essentially all of the company's future revenue potential depends on advancing its clinical-stage pipeline (particularly CELZ-201 and Ultrasome) through trials toward regulatory clearance or broader physician adoption.
Competitive Landscape
Creative Medical Technology competes against a wide range of regenerative-medicine and cell-therapy developers, from large pharmaceutical and biotech companies pursuing similar indications (orthopedic regenerative therapies, immunotherapy platforms, sexual health treatments) to numerous other small-cap and private biotechs working on perinatal- and stem-cell-derived products. In elective procedure categories like CaverStem and FemCelz, it also competes against established medical-device and pharmaceutical treatments for erectile dysfunction and menopause-related symptoms that have far greater physician familiarity and payer/insurance support.
Competitive Position
The company's main asset is a broad portfolio of patented, perinatal-tissue-derived therapeutic platforms addressing several distinct and potentially large markets (sexual health, chronic pain, osteoarthritis, autoimmune disease, diabetes), giving it multiple avenues for a future breakthrough. However, its competitive position today is very weak: negligible revenue, a small four-person team, ongoing significant net losses, and clinical-stage assets that are years away, if ever, from meaningful commercial revenue. As with most micro-cap clinical-stage biotechs, the company's survival and any future value creation depend on securing continued financing, generating positive clinical data (particularly from the ADAPT trial and further Ultrasome studies), and successfully commercializing at least one therapy before cash constraints or competitive/regulatory setbacks become decisive.